We are happy to welcome in our cluster Anavo Therapeutics, the first company to systematically drug phosphatases, a rich target space considered undruggable for decades.
Anavo has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures and Bioqube Ventures.
We are looking forward to see your active participation in the network!
You can find here more information about Anavo Therapeutics.